TargetBeta
SLC18A2
solute carrier family 18 member A2 · also SVMT, SVAT, VAT2, VMAT2 · Solute carrier family 18
3 programs in company-led studies act on SLC18A2, from 3 companies: 0 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| valbenazinerule | Neurocrine Biosciences | phase 4 | 282 running | – | ChEMBL |
| lisdexamfetaminerule | Takeda | phase 4 | 470 running | SLC6A2, SLC6A3 | ChEMBL |
| deutetrabenazinerule | Teva Pharmaceutical Industries | phase 4 | 120 running | – | ChEMBL |
Conditions their studies are in
- Huntington Disease, 2 programs
- Schizophrenia, 2 programs
- Tardive Dyskinesia, 2 programs
- Tourette Syndrome, 2 programs
- Attention Deficit Disorder with Hyperactivity, 1 program
- Binge-Eating Disorder, 1 program
- Cerebral Palsy, 1 program
- Depressive Disorder, Major, 1 program
- Dyskinesias, 1 program
- Sleep Deprivation, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 2028valbenazine · Neurocrine Biosciences · phase 4 · NCT06312189
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.